Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status:
Completed
Trial end date:
2020-04-08
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well combination chemotherapy and ofatumumab work in treating
patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in
chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy
with ofatumumab, may induce changes in body's immune system and may interfere with the
ability of tumor cells to grow and spread. Giving combination chemotherapy together with
ofatumumab may be an effective treatment for acute lymphoblastic leukemia or lymphoblastic
lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals